{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:34:10Z","timestamp":1783398850069,"version":"3.54.6"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T00:00:00Z","timestamp":1488240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ekir.2017.02.019","type":"journal-article","created":{"date-parts":[[2017,3,5]],"date-time":"2017-03-05T02:19:45Z","timestamp":1488680385000},"page":"654-664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)"],"prefix":"10.1016","volume":"2","author":[{"given":"Radko","family":"Komers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie S.","family":"Gipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarak","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal K.","family":"Derebail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin E.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Pergola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan E.","family":"MacNally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Trachtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2017.02.019_bib1","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMra1106556","article-title":"Focal segmental glomerulosclerosis","volume":"365","author":"D\u2019Agati","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2017.02.019_bib2","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1681\/ASN.2014050489","article-title":"A\u00a0single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome","volume":"26","author":"Sadowski","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.02.019_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1053\/j.ackd.2014.05.010","article-title":"Permeability factors in focal and segmental glomerulosclerosis","volume":"21","author":"Reiser","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ekir.2017.02.019_bib4","doi-asserted-by":"crossref","first-page":"2150451","DOI":"10.1155\/2016\/2150451","article-title":"Immunologic changes implicated in the pathogenesis of focal segmental glomerulosclerosis","volume":"2016","author":"Kronbichler","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ekir.2017.02.019_bib5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nrneph.2015.9","article-title":"HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment","volume":"11","author":"Rosenberg","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2017.02.019_bib6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5500\/wjt.v6.i1.54","article-title":"Update on the treatment of focal segmental glomerulosclerosis in renal transplantation","volume":"6","author":"Messina","year":"2016","journal-title":"World J Transplant"},{"key":"10.1016\/j.ekir.2017.02.019_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fped.2016.00025","article-title":"Changing the paradigm for the treatment and development of new therapies for FSGS","volume":"4","author":"Spino","year":"2016","journal-title":"Front Pediatr"},{"key":"10.1016\/j.ekir.2017.02.019_bib8","doi-asserted-by":"crossref","first-page":"Svii","DOI":"10.1053\/j.ajkd.2015.05.001","article-title":"US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States","volume":"66","author":"Saran","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2017.02.019_bib9","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1681\/ASN.2012040389","article-title":"Treatment of primary FSGS in adults","volume":"23","author":"Korbet","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.02.019_bib10","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1093\/ndt\/gfp254","article-title":"The changing pattern of adult primary glomerular disease","volume":"24","author":"Hanko","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2017.02.019_bib11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1053\/j.ackd.2011.03.005","article-title":"Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients","volume":"18","author":"Kiffel","year":"2011","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ekir.2017.02.019_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s004670050555","article-title":"High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood","volume":"13","author":"Srivastava","year":"1999","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2017.02.019_bib13","first-page":"135","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ekir.2017.02.019_bib14","doi-asserted-by":"crossref","first-page":"4192578","DOI":"10.1155\/2016\/4192578","article-title":"Treatment strategies of adult primary focal segmental glomerulosclerosis: a systematic review focusing on the last two decades","volume":"2016","author":"Beer","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ekir.2017.02.019_bib15","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1046\/j.1523-1755.1999.00778.x","article-title":"A\u00a0randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group","volume":"56","author":"Cattran","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.02.019_bib16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ki.2010.485","article-title":"Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life","volume":"79","author":"Gipson","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.02.019_bib17","first-page":"309","article-title":"Treatment of focal segmental glomerulosclerosis","volume":"20","author":"Matalon","year":"2000","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ekir.2017.02.019_bib18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.ackd.2014.01.010","article-title":"Treatment of FSGS in children","volume":"21","author":"Sethna","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ekir.2017.02.019_bib19","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3109\/0886022X.2013.794687","article-title":"Mycophenolate mofetil for primary focal segmental glomerulosclerosis: systematic review","volume":"35","author":"Lau","year":"2013","journal-title":"Ren Fail"},{"key":"10.1016\/j.ekir.2017.02.019_bib20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0272-6386(04)01081-9","article-title":"Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States","volume":"44","author":"Kitiyakara","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2017.02.019_bib21","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.kint.2015.12.058","article-title":"Drug discovery in focal and segmental glomerulosclerosis","volume":"89","author":"Pullen","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.02.019_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrneph.2012.42","article-title":"Proteinuria should be used as a surrogate in CKD","volume":"8","author":"Cravedi","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2017.02.019_bib23","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/ndt\/15.9.1348","article-title":"Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis","volume":"15","author":"Alexopoulos","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2017.02.019_bib24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/ajkd.1998.v32.pm9669427","article-title":"Long-term outcome in children and adults with classic focal segmental glomerulosclerosis","volume":"32","author":"Cattran","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2017.02.019_bib25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00467-005-2097-0","article-title":"Differential risk of remission and ESRD in childhood FSGS","volume":"21","author":"Gipson","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2017.02.019_bib26","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1681\/ASN.2004070593","article-title":"Toronto Glomerulonephritis Registry G: focal and segmental glomerulosclerosis: definition and relevance of a partial remission","volume":"16","author":"Troyanov","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.02.019_bib27","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.02.019_bib28","doi-asserted-by":"crossref","first-page":"R877","DOI":"10.1152\/ajpregu.00425.2015","article-title":"Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease","volume":"310","author":"Komers","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.ekir.2017.02.019_bib29","doi-asserted-by":"crossref","first-page":"F1448","DOI":"10.1152\/ajprenal.00340.2009","article-title":"Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes","volume":"297","author":"Gagliardini","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ekir.2017.02.019_bib30","doi-asserted-by":"crossref","first-page":"F1114","DOI":"10.1152\/ajprenal.00122.2011","article-title":"Distinct cardiac and renal effects of ETA receptor antagonist and ace inhibitor in experimental type 2 diabetes","volume":"301","author":"Zoja","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ekir.2017.02.019_bib31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00467-012-2316-4","article-title":"Endothelin antagonists in hypertension and kidney disease","volume":"28","author":"Meyers","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2017.02.019_bib32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.02.019_bib33","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"Kohan","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.02.019_bib34","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.02.019_bib35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1681\/ASN.2013040362","article-title":"Beta-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury","volume":"25","author":"Buelli","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.02.019_bib36","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1172\/JCI71195","article-title":"Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis","volume":"124","author":"Daehn","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2017.02.019_bib37","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ki.2012.428","article-title":"Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach","volume":"83","author":"Gadegbeku","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.02.019_bib38","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","article-title":"PedsQL 4.0: reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations","volume":"39","author":"Varni","year":"2001","journal-title":"Med Care"},{"key":"10.1016\/j.ekir.2017.02.019_bib39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00005650-199902000-00003","article-title":"The PedsQL: measurement model for the pediatric quality of life inventory","volume":"37","author":"Varni","year":"1999","journal-title":"Med Care"},{"key":"10.1016\/j.ekir.2017.02.019_bib40","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024917300529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024917300529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T17:22:45Z","timestamp":1535995365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024917300529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S2468024917300529"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2017.02.019","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2017.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}